Stock Track | Hims & Hers Health Stock Plummets 25.76% as FDA Ends Ozempic, Wegovy Shortage

Stock Track

Feb 21, 2025

Shares of Hims & Hers Health Inc. (HIMS) plummeted 25.76% in the pre-market trading session on Friday, after the U.S. Food and Drug Administration announced that the shortage of Novo Nordisk's popular weight-loss and diabetes drugs Ozempic and Wegovy has been resolved.

The resolution of the shortage could potentially restrict how telehealth programs like Hims & Hers offer cheaper versions known as compounded drugs, which have seen a boom in demand due to the tight supply of Novo Nordisk's treatments. Regulations allow compounding pharmacies to copy brand-name medicines only when they are in short supply.

With the shortage ending, companies offering compounded versions of semaglutide, the active ingredient in Ozempic and Wegovy, could face challenges. This development poses a threat to Hims & Hers, which offers compounded semaglutide as an alternative to the brand-name drugs.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1125671531"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1125671531\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1125671531?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-21 22:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1125671531","market":"hk","top_or_hot":-1,"title":"Stock Track | Hims & Hers Health Stock Plummets 25.76% as FDA Ends Ozempic, Wegovy Shortage","media":"Stock Track","content":"<p>Shares of Hims & Hers Health Inc. (HIMS) plummeted 25.76% in the pre-market trading session on Friday, after the U.S. Food and Drug Administration announced that the shortage of Novo Nordisk's popular weight-loss and diabetes drugs Ozempic and Wegovy has been resolved.</p>\n\n<p>The resolution of the shortage could potentially restrict how telehealth programs like Hims & Hers offer cheaper versions known as compounded drugs, which have seen a boom in demand due to the tight supply of Novo Nordisk's treatments. Regulations allow compounding pharmacies to copy brand-name medicines only when they are in short supply.</p>\n\n<p>With the shortage ending, companies offering compounded versions of semaglutide, the active ingredient in Ozempic and Wegovy, could face challenges. This development poses a threat to Hims & Hers, which offers compounded semaglutide as an alternative to the brand-name drugs.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Hims & Hers Health Stock Plummets 25.76% as FDA Ends Ozempic, Wegovy Shortage</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Hims & Hers Health Stock Plummets 25.76% as FDA Ends Ozempic, Wegovy Shortage\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-21 22:59</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Hims & Hers Health Inc. (HIMS) plummeted 25.76% in the pre-market trading session on Friday, after the U.S. Food and Drug Administration announced that the shortage of Novo Nordisk's popular weight-loss and diabetes drugs Ozempic and Wegovy has been resolved.</p>\n\n<p>The resolution of the shortage could potentially restrict how telehealth programs like Hims & Hers offer cheaper versions known as compounded drugs, which have seen a boom in demand due to the tight supply of Novo Nordisk's treatments. Regulations allow compounding pharmacies to copy brand-name medicines only when they are in short supply.</p>\n\n<p>With the shortage ending, companies offering compounded versions of semaglutide, the active ingredient in Ozempic and Wegovy, could face challenges. This development poses a threat to Hims & Hers, which offers compounded semaglutide as an alternative to the brand-name drugs.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HIMS","symbol_name":"Hims & Hers Health Inc.","start_time":0,"source_url":"","article_id":"1125671531","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1125671531","pubTimestamp":1740149976,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Hims & Hers Health Inc.  plummeted 25.76% in the pre-market trading session on Friday, after the U.S. Food and Drug Administration announced that the shortage of Novo Nordisk's popular weight-loss and diabetes drugs Ozempic and Wegovy has been resolved.The resolution of the shortage could potentially restrict how telehealth programs like Hims & Hers offer cheaper versions known as compounded drugs, which have seen a boom in demand due to the tight supply of Novo Nordisk's treatments. R","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HIMS":"Hims & Hers Health Inc."},"translate_title":"股票追踪随着FDA结束Ozempic、Wegovy短缺，Hims&Hers Health股价暴跌25.76%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":1},"content_text":"Shares of Hims & Hers Health Inc. (HIMS) plummeted 25.76% in the pre-market trading session on Friday, after the U.S. Food and Drug Administration announced that the shortage of Novo Nordisk's popular weight-loss and diabetes drugs Ozempic and Wegovy has been resolved.\nThe resolution of the shortage could potentially restrict how telehealth programs like Hims & Hers offer cheaper versions known as compounded drugs, which have seen a boom in demand due to the tight supply of Novo Nordisk's treatments. Regulations allow compounding pharmacies to copy brand-name medicines only when they are in short supply.\nWith the shortage ending, companies offering compounded versions of semaglutide, the active ingredient in Ozempic and Wegovy, could face challenges. This development poses a threat to Hims & Hers, which offers compounded semaglutide as an alternative to the brand-name drugs.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}